Table 3.
Clinical patterns of patients by risk categories in the validation cohort.
| Characteristic | Low risk N=1,266,983 |
Intermediate risk N=111,195 |
High risk N=52,594 |
|
| Age, years, median (1st quartile, 3rd quartile) | 39 (20, 56) | 75 (68, 82) | 79 (71, 85) | |
| Female, n (%) | 667,440 (52.68) | 55,717 (50.11) | 25,710 (48.88) | |
| Race, n (%) | ||||
| White | 1,031,954 (81.45) | 110,303 (99.20) | 52,221 (99.29) | |
| Black | 21,151 (1.67) | 424 (0.38) | 195 (0.37) | |
| Asian | 10,332 (0.82) | 253 (0.23) | 92 (0.17) | |
| Other/unknown | 203,546 (16.07) | 215 (0.19) | 86 (0.16) | |
| Diabetes, n (%) | 22,025 (1.74) | 19,271 (17.33) | 19,335 (36.76) | |
| Hypertension, n (%) | 60,970 (4.81) | 39,564 (35.58) | 32,794 (62.35) | |
| Heart disease, n (%) | 17,388 (1.37) | 16,156 (14.53) | 19,236 (36.57) | |
| Obesity, n (%) | 29,308 (2.31) | 6686 (6.01) | 4771 (9.07) | |
| Blood pressure medication, n (%) | 64,974 (5.13) | 42,096 (37.86) | 34,183 (64.99) | |
| Diabetes medication, n (%) | 26,533 (2.09) | 17,045 (15.33) | 15,553 (29.57) | |
| Abnormal diabetes test, n (%) | 575 (0.05) | 388 (0.35) | 618 (1.18) | |
| Abnormal urine albumin-to-creatinine ratio, n (%) | 155 (0.01) | 90 (0.08) | 171 (0.33) | |
| Total costs, median (1st quartile, 3rd quartile) | 170 (0, 925) | 850 (170, 2455) | 1700 (510, 4530) | |
| Outpatient visits, median (1st quartile, 3rd quartile) | 1 (0, 3) | 4 (1, 8) | 8 (4, 15) | |
| Total counts of medications, median (1st quartile, 3rd quartile) | 0 (0, 3) | 7 (0, 31) | 32 (7, 75) | |
| Total counts of laboratory tests, median (1st quartile, 3rd quartile) | 0 (0, 0) | 0 (0, 29) | 6 (0, 81) | |